MDxHealth S.A.
NASDAQ:MDXHMedical - Diagnostics & Research
-$0.03 today
- Market cap
- $57.59M
- Beta
- 0.38
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$0.58
Volume 0.65M
Average 4.27M
MDXH Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
MDxHealth S.A.NASDAQ: MDXH
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization grows 5.6% year over year
Q2 FY2026 depreciation & amortization of $2.39M rose 5.6% year over year. Over 3 fiscal years it compounded at +23.3% a year.
Context
- Depreciation & amortization amounted to 8.5% of revenue in FY2025, down 0.4 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 9.21M USD
- Year-over-year change
- +14.5%
- 4-year CAGR
- +32.0%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.21M | +14.5% |
| FY2024 | 2024-12-31 | 8.04M | +17.2% |
| FY2023 | 2023-12-31 | 6.86M | +39.7% |
| FY2022 | 2022-12-31 | 4.91M | +61.7% |
| FY2021 | 2021-12-31 | 3.04M | — |
Depreciation & Amortization vs competitors
How MDXH compares with its peers on the latest reported figures
- MDXH's FY2025 depreciation & amortization of $9.21M is the 3rd largest of the 11 companies compared; the peer median is $1.06M.
- Its year-over-year change of +14.5% is the 6th highest of 10, against a peer median of +15.1%.
- Depreciation & amortization amounts to 8.5% of revenue for MDXH, versus a peer median of 5.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $65.46M | -8.0% | -0.8% | 8.5% | |
| LTM Mar 2026 | $22.58M | +148.0% | +52.4% | 15.6% | |
| FY2025 | $9.21M | +14.5% | +23.3% | 8.5% | |
| LTM Mar 2026 | $3.67M | — | — | 6.8% | |
| LTM Mar 2026 | $2.28M | +33.5% | +10.8% | 3.3% | |
| LTM Mar 2026 | $1.58M | +31.8% | +53.6% | 5.1% | |
| LTM Mar 2026 | $531.13K | +15.1% | -4.3% | — | |
| LTM Mar 2026 | $528K | -25.9% | -17.1% | 6.3% | |
| LTM Mar 2026 | $122K | -6.2% | -36.3% | 0.2% | |
| LTM Mar 2026 | $103K | -90.0% | +10.5% | 0.2% | |
ZURAZura Bio Limited | LTM Mar 2026 | $56K | +229.4% | — | — |
| Peer median (excluding MDXH) | $1.06M | +15.1% | +4.8% | 5.7% | |
Competitors are the stored peer set for MDXH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (26.84M) | (37.9M) | (27.33M) | (24.72M) | (14.41M) |
| Depreciation & Amortization | 3.04M | 4.91M | 6.86M | 8.04M | 9.21M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.22M | 867K | 665K | 1.73M | 2.21M |
| Change in Working Capital | 360K | (1.57M) | (2.12M) | (3.86M) | 939K |
| Accounts Receivables | (1.38M) | (5.12M) | (1.68M) | (3.23M) | 2.32M |
| Inventory | 413K | (416K) | (452K) | (1.09M) | (1.93M) |
| Accounts Payables | 0 | 0 | 0 | 0 | 550K |
| Other Working Capital | 1.33M | 3.97M | 20K | 458K | 0 |
| Other Non-Cash Items | (325K) | (429K) | 421K | 286K | (8.37M) |
| Operating Cash Flow | (22.55M) | (34.12M) | (21.5M) | (18.53M) | (10.42M) |
| Capital Expenditures | (896K) | (4.16M) | (5.02M) | (2.16M) | (1.16M) |
| Acquisitions (Net) | 0 | (25M) | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 11K | (1.25M) | (1.18M) | (448K) | (18.9M) |
| Investing Cash Flow | (885K) | (29.04M) | (3.93M) | (1.64M) | (20.06M) |
| Debt Repayment | (1.06M) | 22.13M | (3.27M) | 11.59M | 21.6M |
| Common Stock Issued | 68.57M | 0 | 39.6M | 40.74M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.01M) | (1.41M) | (4.05M) | (7.73M) | (8.91M) |
| Financing Cash Flow | 66.5M | 20.72M | 32.28M | 44.6M | 12.7M |
| Effect of Forex Changes | (520K) | (555K) | 25K | (14K) | 16K |
| Net Change in Cash | 42.55M | (43M) | 6.88M | 24.42M | (17.77M) |
| Free Cash Flow | (23.44M) | (38.28M) | (26.52M) | (20.69M) | (11.57M) |
MDxHealth S.A.
NASDAQ:MDXH
Intrinsic Alpha fair value
Locked
Current Price
$0.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.